DK2971045T3 - Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen - Google Patents
Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen Download PDFInfo
- Publication number
- DK2971045T3 DK2971045T3 DK14776084.7T DK14776084T DK2971045T3 DK 2971045 T3 DK2971045 T3 DK 2971045T3 DK 14776084 T DK14776084 T DK 14776084T DK 2971045 T3 DK2971045 T3 DK 2971045T3
- Authority
- DK
- Denmark
- Prior art keywords
- recombinant
- compositions
- methods
- tumor antigen
- cell receptors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361778673P | 2013-03-13 | 2013-03-13 | |
PCT/US2014/025673 WO2014160030A2 (en) | 2013-03-13 | 2014-03-13 | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2971045T3 true DK2971045T3 (da) | 2019-09-16 |
Family
ID=51625624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14776084.7T DK2971045T3 (da) | 2013-03-13 | 2014-03-13 | Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen |
Country Status (7)
Country | Link |
---|---|
US (3) | US10000546B2 (da) |
EP (2) | EP2971045B1 (da) |
JP (2) | JP6464140B2 (da) |
CA (1) | CA2906587C (da) |
DK (1) | DK2971045T3 (da) |
ES (1) | ES2746240T3 (da) |
WO (1) | WO2014160030A2 (da) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6464140B2 (ja) * | 2013-03-13 | 2019-02-06 | ヘルス リサーチ インコーポレイテッドHealth Research, Inc. | 腫瘍抗原を直接認識するために組換えt細胞レセプターを使用するための組成物及び方法 |
CA2964948A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
US20190169637A1 (en) * | 2015-09-22 | 2019-06-06 | Julius-Maximilians-Universität Würzburg | A method for high level and stable gene transfer in lymphocytes |
WO2017076308A1 (zh) * | 2015-11-04 | 2017-05-11 | 广州市香雪制药股份有限公司 | 识别ny-eso-1抗原短肽的tcr |
GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
AU2017205637B2 (en) * | 2016-01-06 | 2023-01-05 | Health Research, Inc. | Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors |
JP7254519B2 (ja) | 2016-04-08 | 2023-04-10 | イムノコア リミテッド | T細胞レセプター |
WO2017201488A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
GB201617716D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | Cell |
GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
WO2018098354A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
EP3565831A4 (en) * | 2016-12-29 | 2021-01-13 | Board Of Regents, The University Of Texas System | HLA RESTRICTED VCX / Y-PEPTIDES AND T-CELL RECEPTORS AND USES |
EP3568412A2 (en) | 2017-01-13 | 2019-11-20 | Agenus Inc. | T cell receptors that bind to ny-eso-1 and methods of use thereof |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US11702459B2 (en) | 2017-03-07 | 2023-07-18 | Universität Basel | MR1 restricted T cell receptors for cancer immunotherapy |
CA3054758A1 (en) * | 2017-03-07 | 2018-09-13 | Universitat Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
US10255011B2 (en) * | 2017-03-10 | 2019-04-09 | Xerox Corporation | Methods and systems for applying spot color on one or more pages as specified by a user |
WO2018170338A2 (en) * | 2017-03-15 | 2018-09-20 | Fred Hutchinson Cancer Research Center | High affinity mage-a1-specific tcrs and uses thereof |
CA3059643A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
CN108103106A (zh) * | 2018-01-09 | 2018-06-01 | 河南省华隆生物技术有限公司 | 一种pFTM3GW重组载体及其制备方法和应用 |
EP3749349A4 (en) * | 2018-02-10 | 2021-11-24 | Berkeley Lights, Inc. | MUTANT IDH1 SPECIFIC T CELL RECEPTOR |
CA3090917A1 (en) * | 2018-02-26 | 2019-08-29 | Medigene Immunotherapies Gmbh | Nyeso tcr |
US11046068B2 (en) | 2018-02-26 | 2021-06-29 | Fanatics, Inc. | Direct-to-transfer printing system and process, and components and ASR system therefor |
EP3790571A4 (en) * | 2018-05-03 | 2022-01-19 | University Of Utah Research Foundation | OCA-B PEPTIDE CONJUGATES AND METHODS OF TREATMENT |
WO2019217831A1 (en) * | 2018-05-11 | 2019-11-14 | Memorial Sloan-Kettering Cancer Center | Methods for identifying antigen-specific t cell receptors |
KR20210057750A (ko) * | 2018-09-12 | 2021-05-21 | 유니버시타트 바셀 | 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체 |
US20220054544A1 (en) * | 2018-09-21 | 2022-02-24 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
EP3870602A1 (en) * | 2018-10-23 | 2021-09-01 | Regeneron Pharmaceuticals, Inc. | Ny-eso-1 t cell receptors and methods of use thereof |
US20220098268A1 (en) * | 2019-01-15 | 2022-03-31 | Altor Bioscience, Llc | Human immunodeficiency virus-specific t cell receptors |
KR20210149051A (ko) * | 2019-03-04 | 2021-12-08 | 유니버시티 헬스 네트워크 | T 세포 수용체 및 이의 사용 방법 |
MX2022000081A (es) * | 2019-07-03 | 2022-04-27 | Regeneron Pharma | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso. |
US11180563B2 (en) | 2020-02-21 | 2021-11-23 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830755A (en) * | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
AU2043201A (en) | 1999-11-16 | 2001-05-30 | General Hospital Corporation, The | Compositions and methods for regulating tumor-associated antigen expression |
CA2398743C (en) * | 2000-01-28 | 2015-06-23 | The Government Of The United States Of America | Novel mhc class ii restricted t cell epitopes from the cancer antigen, ny eso-1 |
CA2475206A1 (en) | 2002-02-15 | 2003-08-15 | The General Hospital Corporation | Map-kinase inhibitors as regulators of tumor-associated antigen expression |
JP2006506442A (ja) | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス, インコーポレイテッド | ボロプロリン化合物併用療法 |
ES2399749T3 (es) | 2002-08-29 | 2013-04-03 | Cytocure Llc | Composiciones farmacéuticas que comprenden Interferón beta para su uso en el tratamiento de melanoma |
CA2566363C (en) | 2004-05-19 | 2014-12-16 | Avidex Ltd | High affinity ny-eso t cell receptor |
WO2006031221A1 (en) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
GB0524477D0 (en) * | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
US20090304657A1 (en) * | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
PT2520168E (pt) * | 2006-07-21 | 2014-04-29 | California Inst Of Techn | Administração de gene alvo para vacinação de células dendríticas |
WO2009003493A2 (en) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
WO2010037397A1 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
US8785601B2 (en) * | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
EP2408819A2 (en) | 2009-03-20 | 2012-01-25 | Ludwig Institute for Cancer Research Ltd | High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof |
WO2011040978A2 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
SI2618835T1 (sl) * | 2010-09-20 | 2017-10-30 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t celični receptorji in t celični epitopi |
JP6464140B2 (ja) * | 2013-03-13 | 2019-02-06 | ヘルス リサーチ インコーポレイテッドHealth Research, Inc. | 腫瘍抗原を直接認識するために組換えt細胞レセプターを使用するための組成物及び方法 |
-
2014
- 2014-03-13 JP JP2016501939A patent/JP6464140B2/ja active Active
- 2014-03-13 WO PCT/US2014/025673 patent/WO2014160030A2/en active Application Filing
- 2014-03-13 ES ES14776084T patent/ES2746240T3/es active Active
- 2014-03-13 CA CA2906587A patent/CA2906587C/en active Active
- 2014-03-13 US US14/774,723 patent/US10000546B2/en active Active
- 2014-03-13 EP EP14776084.7A patent/EP2971045B1/en active Active
- 2014-03-13 EP EP18182389.9A patent/EP3404111A1/en active Pending
- 2014-03-13 DK DK14776084.7T patent/DK2971045T3/da active
-
2018
- 2018-06-14 US US16/008,858 patent/US11155595B2/en active Active
- 2018-12-27 JP JP2018244112A patent/JP6612963B2/ja active Active
-
2021
- 2021-10-07 US US17/496,580 patent/US20220017593A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016512435A (ja) | 2016-04-28 |
EP3404111A1 (en) | 2018-11-21 |
WO2014160030A3 (en) | 2014-11-27 |
EP2971045B1 (en) | 2019-06-19 |
US10000546B2 (en) | 2018-06-19 |
US20190002522A1 (en) | 2019-01-03 |
EP2971045A2 (en) | 2016-01-20 |
WO2014160030A2 (en) | 2014-10-02 |
CA2906587A1 (en) | 2014-10-02 |
US11155595B2 (en) | 2021-10-26 |
JP2019080568A (ja) | 2019-05-30 |
US20160024174A1 (en) | 2016-01-28 |
US20220017593A1 (en) | 2022-01-20 |
EP2971045A4 (en) | 2016-10-19 |
JP6612963B2 (ja) | 2019-11-27 |
JP6464140B2 (ja) | 2019-02-06 |
CA2906587C (en) | 2023-02-14 |
ES2746240T3 (es) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2971045T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen | |
DK3896091T3 (da) | Kimære antigenreceptorer målrettet bcma og fremgangsmåder til anvendelse deraf | |
DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
DK3292149T3 (da) | Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
DK3148579T3 (da) | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf | |
DK3083689T3 (da) | Anti-CD3-antistoffer og fremgangsmåder til anvendelse | |
DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3514172T3 (da) | Claudin-6-specifikke immunoreceptorer og t-celleepitoper | |
DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
DK3126394T3 (da) | Anti-OX40-antistoffer og fremgangsmåder til anvendelse | |
DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
DK3262071T3 (da) | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater | |
DK3230319T3 (da) | Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3035955T3 (da) | Sammensætning og vaccine til behandling af lungekræft | |
DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
DK3019200T3 (da) | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf | |
DK3087095T3 (da) | FcRn-antagonist og fremgangsmåder til anvendelse |